FDA Talks Drug Safety With China, But Visas Still Elusive For Staff

The agency is unable to place more inspectors in China even as Howard Sklamberg, deputy commissioner for global regulatory operations and policy, visits Beijing.

FDA efforts to bolster its oversight of drug manufacturers in China remain partially hamstrung by ongoing delays in allowing permanent stations for its personnel there.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

More from Asia